INHIBITORY EFFECTS OF ANTIHYPERTENSIVE DRUGS ON MESANGIAL CELL-PROLIFERATION AFTER ANTI-THYMOCYTE SERUM (ATS)-INDUCED MESANGIOLYSIS IN SPONTANEOUSLY HYPERTENSIVE RATS
S. Kiyama et al., INHIBITORY EFFECTS OF ANTIHYPERTENSIVE DRUGS ON MESANGIAL CELL-PROLIFERATION AFTER ANTI-THYMOCYTE SERUM (ATS)-INDUCED MESANGIOLYSIS IN SPONTANEOUSLY HYPERTENSIVE RATS, Life sciences, 54(24), 1994, pp. 1891-1900
Citations number
28
Categorie Soggetti
Biology,"Medicine, Research & Experimental","Pharmacology & Pharmacy
The effects of antihypertensive drugs on mesangial cell proliferation
were studied in spontaneously hypertensive rats (SHR) with anti-thymoc
yte serum (ATS)-induced glomerulo-nephritis. Rats were treated with ei
ther enalapril (Group 1), nifedipine (Group 2), or reserpine + hydroch
lorothiazide + hydralazine (Group 3), or were untreated (Group 4). The
animals were sacrificed 2, 4 and 7 days after ATS injection and the g
lomerular cell number and degree of mesangial area expansion were exam
ined. A marked, similar decrease in glomerular nuclear cell number (NC
) due to severe mesangiolysis was observed in all of the groups on day
2. Thereafter, an increase in NC reflecting mesangial cell proliferat
ion after mesangiolysis occurred in Group 4 on days 4 and 7. In groups
1 and 2, the NC was significantly smaller than that in Group 4 on day
s 4 and 7, indicating suppression of mesangial cell proliferation. In
Group 3, however, the number of NCs did not differ from that in Group
4 on days 4 and 7, indicating a lack of such suppression by convention
al antihypertensive drugs. The degree of mesangial area expansion (MS)
showed the same pattern as mesangial cell proliferation. That is, the
rapid increases in MS seen in Group 4 on days 4 and 7 were apparently
suppressed in Groups 1 and 2, but not in Group 3. Our in vivo observa
tions that both an angiotensin converting enzyme (ACE) inhibitor and a
calcium channel blocker suppress mesangial cell proliferation and mes
angial area expansion suggest that these agents have practical implica
tions in the treatment of mesangial proliferative glomerular diseases
through the suppression of excess mesangial cell proliferation.